Core Focus and Mission

Genexine's mission centers on developing innovative biologic medicines that address unmet medical needs. The company emphasizes the creation of therapeutics with improved efficacy, extended half-life, and enhanced patient convenience. By leveraging its in-house technology platforms, Genexine aims to differentiate its products from existing treatments and deliver value across oncology, immunology, and vaccine development.

Proprietary Technology Platforms

Genexine's research and development efforts are built upon several core proprietary platform technologies that serve as the foundation for its pipeline.

hyFc Technology

The hyFc (hybrid Fc) platform is one of Genexine's flagship technologies. This long-acting drug development platform extends the half-life of therapeutic proteins by fusing them with a hybrid antibody Fc fragment. The technology is designed to reduce the frequency of drug administration, improving patient compliance and convenience while minimizing immunogenicity concerns. The hyFc platform has been applied to multiple candidates in the company's pipeline, including long-acting growth hormone and other fusion proteins.

DNA Vaccine Platform

Genexine has invested significantly in DNA-based vaccine and immunotherapy technologies. This platform is utilized to develop vaccines and therapeutic candidates that stimulate targeted immune responses, with applications spanning infectious diseases and cancer immunotherapy. The DNA vaccine approach is designed to generate robust cellular and humoral immunity.

Immuno-Oncology Approaches

The company also develops cytokine-based and immune-modulating therapeutics aimed at enhancing the body's immune system to fight cancer. These approaches include engineered cytokines and fusion proteins designed to activate immune cells while limiting systemic toxicity.

Key Products and Pipeline Candidates

Genexine maintains a broad pipeline of clinical and preclinical candidates across several therapeutic areas.

GX-H9 (Long-Acting Human Growth Hormone)

GX-H9 is a long-acting recombinant human growth hormone developed using the hyFc platform. It is designed to treat growth hormone deficiency in both pediatric and adult patients. The long-acting formulation aims to reduce the burden of daily injections that characterize conventional growth hormone treatments, offering a weekly or biweekly dosing schedule to improve patient adherence.

GX-I7 / Efineptakin Alfa (Long-Acting Interleukin-7)

One of Genexine's most notable candidates is GX-I7, also known as efineptakin alfa, a long-acting recombinant interleukin-7 (IL-7). IL-7 is a cytokine that plays a critical role in the proliferation and survival of T cells, key components of the immune system. GX-I7 is being developed for a range of applications, including immuno-oncology in combination with other therapies, and as a means to boost immune function in conditions involving lymphopenia. The candidate has been studied in various cancer indications and has attracted attention for its potential to enhance immune responses.

GX-188E (Therapeutic DNA Vaccine)

GX-188E is a therapeutic DNA vaccine developed for the treatment of human papillomavirus (HPV)-related diseases, including cervical precancerous lesions and cervical cancer. The candidate is designed to elicit targeted immune responses against HPV antigens, offering a potential non-surgical treatment option for HPV-associated conditions.

COVID-19 Vaccine Development

During the global COVID-19 pandemic, Genexine engaged in the development of a DNA-based vaccine candidate aimed at providing protection against SARS-CoV-2. This effort leveraged the company's DNA vaccine platform expertise and represented part of South Korea's broader response to the pandemic.

Additional Pipeline Programs

Beyond its lead candidates, Genexine has pursued various other biologic and immunotherapy programs, including long-acting versions of other therapeutic proteins and immuno-oncology combinations. The company continually evaluates and advances new candidates derived from its platform technologies.

Business Model and Partnerships

Genexine operates a business model that combines internal research and development with strategic collaborations and licensing arrangements. The company has entered into partnerships with domestic and international pharmaceutical and biotechnology firms to co-develop, license, and commercialize its candidates. These collaborations help share development costs, expand geographic reach, and accelerate the path to market for promising therapeutics.

The company has also established affiliations and joint ventures to broaden its capabilities and access new markets. Genexine has been associated with related ventures in the broader biopharmaceutical ecosystem, including contract development and manufacturing capabilities and regional expansion efforts in Asia.

Research and Development

As a clinical-stage company, Genexine dedicates substantial resources to research and development. Its R&D activities encompass discovery research, preclinical studies, and the management of clinical trials across multiple phases. The company conducts trials both domestically in South Korea and internationally, working with academic institutions, hospitals, and contract research organizations to evaluate the safety and efficacy of its candidates.

The scientific foundation of the company, rooted in its origins at KAIST, continues to inform its approach to innovation and its emphasis on platform-driven drug development.

Industry Position

Genexine occupies a notable position within South Korea's growing biopharmaceutical industry, which has emerged as a significant hub for biotechnology innovation in Asia. The company is recognized for its focus on long-acting biologics and immunotherapy, areas that represent important trends in modern drug development. By maintaining a diversified pipeline and proprietary technology platforms, Genexine seeks to establish itself as a competitive player in the global biopharmaceutical landscape.

Summary

Genexine Inc. is a South Korean biopharmaceutical company committed to developing innovative protein therapeutics, immunotherapies, and DNA vaccines. Through its proprietary platforms such as hyFc and its DNA vaccine technology, the company has built a pipeline addressing oncology, immunology, infectious diseases, and endocrine disorders. With candidates including GX-H9 for growth hormone deficiency, GX-I7 (efineptakin alfa) for immuno-oncology, and GX-188E for HPV-related diseases, Genexine continues to pursue its goal of delivering differentiated biologic medicines that improve patient outcomes and quality of life. Supported by strategic partnerships and a strong scientific heritage, the company remains an active contributor to the advancement of next-generation biotherapeutics.